Peptides for Age-Related Macular Degeneration & Eye Disease

Age-related macular degeneration destroys central vision in roughly 200 million people worldwide, and that number is projected to reach 288 million by 2040. Current treatments for the wet form (anti-VEGF injections) are effective but burdensome, requiring repeated intravitreal injections for life. For the dry form, which accounts for 85-90% of all AMD cases, treatment options remain severely limited. Two complement inhibitors (pegcetacoplan and avacincaptad pegol) received FDA approval in 2023 for geographic atrophy, but they only slow progression by roughly 20-30% and carry ocular side effect risks.

Peptide-based therapies are approaching AMD from fundamentally different angles: mitochondrial rescue, retinal ganglion cell neuroprotection, angiogenesis modulation, and cellular senescence reversal. Several are in active clinical trials. Others remain preclinical but rest on compelling mechanistic logic.

The Mitochondrial Theory of AMD

Before examining specific peptides, the disease mechanism matters. The retinal pigment epithelium (RPE) is a single layer of cells sitting between the photoreceptors and the choroidal blood supply. It performs critical housekeeping: phagocytosing shed photoreceptor outer segments, recycling visual pigments, transporting nutrients, and maintaining the outer blood-retinal barrier. It is one of the most metabolically active cell types in the body.

RPE cells depend heavily on mitochondrial oxidative phosphorylation. Over decades, cumulative oxidative damage — from light exposure, lipofuscin accumulation, and the inherently high metabolic demand — degrades mitochondrial DNA (mtDNA) in RPE cells. Unlike nuclear DNA, mtDNA has limited repair mechanisms and no protective histones. Studies by Liang and Godley (2003) demonstrated that human RPE cells accumulate significantly more mtDNA damage than nuclear DNA damage under equivalent oxidative stress.

This mitochondrial decline triggers a cascade: reduced ATP production, increased reactive oxygen species (ROS) generation, chronic inflammation via complement activation and inflammasome signaling, and ultimately RPE cell death. As RPE cells fail, the photoreceptors they support die, producing the characteristic geographic atrophy of dry AMD.

Research from Zhao et al. (2011) at the Harkness Eye Institute showed that targeted mitochondrial oxidative stress in RPE led to metabolic dysfunction in both the RPE and the overlying photoreceptors, confirming that RPE mitochondrial failure is sufficient to drive retinal degeneration. This is the core rationale behind mitochondria-targeted peptide therapies.

SS-31 (Elamipretide): Mitochondrial Rescue in Clinical Trials

Elamipretide (formerly SS-31, brand name under development by Stealth BioTherapeutics) is the furthest advanced peptide therapy for dry AMD. It is a mitochondria-targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that concentrates roughly 1000-fold in the inner mitochondrial membrane within minutes of administration.

Mechanism

Elamipretide binds selectively to cardiolipin, a phospholipid unique to the inner mitochondrial membrane that is essential for electron transport chain (ETC) function. In aging and disease, cardiolipin becomes oxidized and structurally disorganized, impairing ETC complex assembly. Elamipretide stabilizes cardiolipin-dependent cristae structure, restoring efficient electron transfer, increasing ATP production, and reducing electron leak that generates ROS. It does not act as a conventional antioxidant — it corrects the structural basis of mitochondrial dysfunction.

Clinical Evidence

ReCLAIM (Phase 1): The first human trial in dry AMD, published in Ophthalmology Science, enrolled 40 subjects with noncentral geographic atrophy. Patients received daily subcutaneous elamipretide (40 mg) for 24 weeks. The study established safety and showed statistically significant improvements in low-luminance visual acuity (LLVA) — a functional measure of how well patients see in dim conditions, which is among the earliest clinical impairments in AMD. Improvements in LLVA of 4-6 letters (ETDRS) were observed, with some patients gaining substantially more.

ReCLAIM-2 (Phase 2): Published in October 2024, this randomized, placebo-controlled, double-masked trial evaluated 48 weeks of daily subcutaneous elamipretide (40 mg) in patients with dry AMD and noncentral geographic atrophy. The trial assessed geographic atrophy growth rates, ellipsoid zone integrity, and visual function. Results showed signals of ellipsoid zone recovery in a subset of patients — a finding considered remarkable because the ellipsoid zone represents the mitochondria-rich inner segments of photoreceptors, and its restoration implies functional cellular recovery rather than merely slowed degeneration.

ReNEW and ReGAIN (Phase 3): As of March 2025, Stealth BioTherapeutics announced reaching the 50% enrollment milestone in its global Phase 3 program. These trials randomize 360 patients 2:1 to elamipretide versus placebo for 96 weeks, with the option to continue into the open-label ReTAIN extension study. Primary endpoints include best-corrected visual acuity (BCVA) change and geographic atrophy growth rate. Results are expected in late 2026 or early 2027.

Practical Significance

Elamipretide is the only AMD therapy attempting to reverse mitochondrial dysfunction rather than block a downstream consequence. If Phase 3 results confirm Phase 2 signals, it would represent a mechanistic shift in AMD treatment — addressing the disease's root metabolic pathology rather than its inflammatory or angiogenic sequelae.

Safety note: Elamipretide is an investigational drug. Subcutaneous injection site reactions were the most common adverse event in clinical trials. It is not available for self-administration and should only be used within approved clinical trial settings.

Humanin: Retinal Ganglion Cell Neuroprotection

Humanin is a 24-amino-acid mitochondrial-derived peptide (MDP) encoded by the 16S ribosomal RNA gene of mtDNA. Originally discovered in 2001 for its ability to protect neurons against amyloid-beta toxicity in Alzheimer's disease, its neuroprotective properties extend to retinal cells.

Retinal Research

Studies published in the Journal of Molecular Neuroscience demonstrated that humanin protects transformed retinal ganglion cells (RGC-5) from cobalt chloride (CoCl2)-induced apoptosis — a model of hypoxic retinal injury. Humanin attenuated both cell viability loss and apoptotic signaling under hypoxic conditions, suggesting direct neuroprotective activity in retinal neurons.

The mechanism appears to involve multiple pathways: humanin binds to the BAX protein to prevent mitochondrial outer membrane permeabilization, activates the STAT3 signaling cascade through its receptor complex (CNTFR/WSX-1/gp130), and suppresses JNK-mediated apoptotic pathways. In retinal tissue, where mitochondrial stress and oxidative damage drive progressive cell death, these anti-apoptotic properties are particularly relevant.

Relevance to AMD and Glaucoma

Humanin circulating levels decline with age — precisely when AMD risk increases. In the retina, humanin's protective effects extend beyond ganglion cells to RPE cells, where it reduces oxidative stress-induced apoptosis. A patent filed by Bhatt et al. (US 10,059,742) covers the use of humanin and its analogs specifically for preventing retinal disorders.

More potent synthetic analogs, particularly HNG (S14G-humanin), show enhanced neuroprotective activity at lower concentrations. However, all humanin research for ocular conditions remains preclinical. No human clinical trials for AMD or glaucoma have been completed. The peptide's short half-life in circulation and the challenge of delivering adequate concentrations to the posterior segment of the eye remain significant translational hurdles.

Anti-VEGF Peptides for Wet AMD

Wet (neovascular) AMD results from choroidal neovascularization — pathological blood vessel growth beneath the retina driven primarily by vascular endothelial growth factor (VEGF). Current standard-of-care involves intravitreal injections of anti-VEGF proteins (ranibizumab, aflibercept, brolucizumab) every 4-16 weeks.

Peptide-Based Alternatives

AXT107 is a synthetic collagen IV-derived peptide that distinguishes itself from existing anti-VEGF therapies by targeting three signaling pathways simultaneously: VEGFR2, c-Met, and PDGFR-beta. In preclinical studies published by researchers at Johns Hopkins, AXT107 demonstrated anti-angiogenic effects lasting roughly twice as long as aflibercept (Eylea) in animal models of choroidal neovascularization. AXT107 self-assembles into a slow-release gel upon intravitreal injection, potentially extending treatment intervals significantly.

Integrin-binding peptides represent another peptide-based approach. Integrins (particularly alpha-v-beta-3 and alpha-v-beta-5) are critical for endothelial cell migration and new vessel formation. Cyclic RGD peptides that block integrin signaling have shown anti-angiogenic activity in choroidal neovascularization models, though none have reached late-stage clinical trials for AMD.

Dendrimer-peptide conjugates are being explored for systemic (non-intravitreal) delivery. A 2023 study in Pharmaceutics demonstrated that hydroxyl dendrimer-conjugated anti-angiogenic peptides could selectively target activated macrophages and RPE in choroidal neovascularization when delivered systemically — potentially eliminating the need for repeated eye injections entirely.

Limitations

Despite the promise of longer-acting and potentially systemically delivered peptide anti-angiogenics, none have yet matched the clinical track record of established anti-VEGF antibodies in human trials. The peptide approaches remain in early-to-mid-stage development.

Epitalon: Telomere Maintenance in Retinal Cells

Epitalon (also spelled epithalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the amino acid sequence of epithalamin, a bovine pineal gland extract studied extensively by Russian gerontologist Vladimir Khavinson.

Telomerase Activation

The core claim behind epitalon is telomerase reactivation. A 2003 study by Khavinson et al. demonstrated that epitalon increased telomerase activity approximately 2.4-fold in human fetal fibroblasts and pulmonary epithelial cells. Critically, the same research group reported telomerase activation specifically in human retinal pigment epithelial cell cultures. In a 2025 study from Brunel University London — the first detailed independent investigation outside of Khavinson's group — epitalon was confirmed to increase telomere length in human cell lines through both telomerase upregulation and alternative lengthening of telomeres (ALT) mechanisms.

RPE-Specific Research

A 2025 study by Gatta et al. evaluated epitalon in ARPE-19 cells (a human retinal pigment epithelial cell line) exposed to high glucose-induced oxidative stress. Epitalon treatment reduced intracellular ROS generation in a concentration-dependent manner, upregulated antioxidant gene expression, and enhanced wound healing in damaged RPE monolayers. These findings suggest potential relevance for diabetic retinopathy in addition to AMD.

Evidence Quality Concerns

Epitalon research warrants significant caution. The majority of published data originates from a single research group (Khavinson and collaborators), and much of the foundational work was published in low-impact journals with limited methodological transparency by Western standards. The 2025 Brunel University study represents a positive step toward independent validation, but the peptide has never been tested in any human clinical trial for AMD, retinal disease, or any other ophthalmic indication. Telomere biology in RPE cells is complex — telomerase activation in post-mitotic or slowly cycling cells does not automatically translate to functional rejuvenation. Claims about epitalon reversing retinal aging remain speculative.

GHK-Cu: Peripheral Support

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is included in AMD discussions primarily for its broad anti-inflammatory and tissue-remodeling properties rather than any direct retinal therapeutic evidence.

In vitro studies show GHK-Cu protecting RPE cells from oxidative stress and UV damage. The peptide reduces NF-kB-mediated inflammatory signaling and modulates metalloproteinase activity — both relevant to the chronic inflammatory environment that characterizes AMD. However, there are no clinical trials or even robust animal studies evaluating GHK-Cu for any retinal condition. Its inclusion in eye-health discussions should be understood as mechanistic extrapolation, not evidence-based therapy.

Emerging Peptide Approaches

Several additional peptide strategies are in early research stages:

Peptain-1

A small peptide derived from alpha-A-crystallin that exhibits chaperone and anti-apoptotic activity. Studies published in Cell Death & Discovery (2019) demonstrated that systemically administered peptain-1 inhibited retinal ganglion cell death in multiple animal models of glaucoma. Follow-up research (2024) elucidated mechanisms involving inhibition of caspase-3 activation and preservation of mitochondrial membrane potential. While not directly tested in AMD, its neuroprotective profile is relevant to retinal degenerative diseases broadly.

Complement-Targeting Peptides

Given the central role of complement dysregulation in AMD pathogenesis (multiple AMD risk genes encode complement proteins), synthetic peptides that inhibit specific complement components (C3, C5, factor D) represent a logical therapeutic direction. Pegcetacoplan, while technically a cyclic peptide-PEG conjugate, validates this approach — it targets C3 and received FDA approval for geographic atrophy in 2023.

Neuroprotectin D1 Analogs

Though technically a lipid mediator rather than a peptide, the success of DHA-derived neuroprotectin D1 in protecting RPE and photoreceptors from oxidative death has inspired peptide mimetic research aimed at achieving similar downstream signaling effects with improved pharmacokinetic properties.

Practical Summary

The peptide landscape for AMD and retinal disease breaks down into clear evidence tiers:

Active clinical trials: Elamipretide (SS-31) is the only peptide in Phase 3 trials for dry AMD. Its mechanism — stabilizing mitochondrial cardiolipin to restore RPE bioenergetics — directly addresses the metabolic root of the disease. Phase 3 results will be decisive.

Strong preclinical rationale: Humanin and its analogs demonstrate consistent retinal neuroprotection in cell and animal models but face delivery challenges for human use. Anti-VEGF peptides like AXT107 show promise for longer-acting wet AMD treatment.

Early-stage or speculative: Epitalon has intriguing RPE cell culture data but lacks clinical evidence and suffers from limited independent validation. GHK-Cu has theoretical relevance through anti-inflammatory mechanisms but no retinal-specific clinical data.

Key caveats: None of these peptides, including elamipretide, are approved for AMD treatment as of mid-2026. Self-administration of research peptides for eye disease carries serious risk — the retina is an immunologically privileged, delicate tissue where even small adverse events can cause irreversible vision loss. Patients with AMD should work with a retinal specialist and consider clinical trial enrollment as the safest path to accessing investigational therapies.

The convergence of mitochondrial medicine, neuroprotective peptides, and next-generation anti-angiogenics suggests that the AMD treatment landscape will look substantially different within the next five years. For now, the evidence demands cautious optimism — and patience for the clinical trial data that will separate genuine breakthroughs from mechanistic speculation.